1MILLER A D.Human gene therapy comes of age[J].Nature,1992,357(6378):455-460.
2BLAESE M,BLANKENSTEIN T,BRENNER M,et al.Vectors in cancer therapy: how will they deliver?[J].Cancer Gene Ther,1995,2(4):291-297.
3HAECHER SE,STEDMAN H H,BALICE-GOR-DON R J,et al.In vivo expression of full-length human dystrophin from adenoviral vectors deleted of all viral genes[J].Hum Gene Ther,1996,7(15):1907-1914.
4PATIJN G A,KAY M A.Hepatic gene therapy using adeno-associated virus vectors[J].Semin Liver Dis,1999,19(1):61-69.
5STRAYER D S,ZERN M A.Gene delivery to the liver using simian virus 40-derived vectors[J].Semin Liver Dis,1999,19(1):71-81.
6WU J,ZERN M A.Modification of liposomes for liver targeting[J].J Hepatol,1996,24(6):757-763.
7CRESPO J,BLAYA C,CRESPO A,et al.Long-term expression of the alpha1-antitrypsin gene in mice employing anionic and cationic liposome vectors[J].Biochem Pharmacol,1996,51(10):1309-1314.
8WU J,WU G Y,ZERN M A.The prospects of hepatic drug delivery and gene therapy[J].Exp Opin Drugs,1998,7(11):1795-1817.
9PAILLARD F.Oligoplexes: Nonviral vehicles for receptor-mediated delivery[J].Hum Gene Ther,1998,9(7):987-988.
10HARA T,TAN Y,HUANG L.In vivo gene delivery to the liver using reconstituted chylomecron remnants as a novel nonviral vector[J].Proc Natl Acad Sci,1997,94(26):14547-14552.
